Despite innovations in the field of diagnostics and targeted therapy, the prognosis of older or relapsed AML patients in particular is often poor. The prospective preservation of biomaterial, especially for multi-omics analyses in the context of clinical studies and registries, represents a crucial pillar for future translational research projects to improve the prognosis of AML patients.

A key aim of the project is to collect samples from individual patients in the longitudinal course of their disease or therapy.

On the one hand, there is great interest in such longitudinal courses in all centers due to the high scientific value, on the other hand, complete sample sets are only available for very few patients. This aspect represents a considerable added value of BZKF biobanking, which creates optimal synergies between the participating centers. Regulatory aspects such as data protection, ethics and quality assurance must be taken into account. The aim is therefore to develop the necessary infrastructure and establish a longitudinal, harmonized and quality-assured biomaterial collection for AML at the BZKF.

AML biobanking

• Harmonization of sample preservation
• Establishment of a collection system on the Confluence collaboration platform
• Continuous recruitment (N=120)